Perspective Therapeutics, Inc.
CATX Healthcare Medical Devices
Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 72.1%, EPS grew 24.1%, free cash flow fell 66.1% and total debt fell 3.57%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CATX
Perspective Therapeutics, Inc. (CATX) EV/Sales
As of 16 October 2026, Perspective Therapeutics, Inc. (CATX) trades at a EV/Sales of 64.7×. Over the past ten years it has ranged from −58.7× (April 2025) to 522× (September 2024); the current reading is higher than 79% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 67.7× | — |
| FY2024 | −13.6× | — |
| FY2023 | 69.4× | — |
| FY2022 | −1.1× | — |
| FY2021 | 76.3× | 96.04% |
| FY2020 | 38.9× | 5.66% |
| FY2019 | 36.9× | (8.77%) |
| FY2018 | 40.4× | (43.54%) |
| FY2017 | 71.6× | (27.16%) |
| FY2016 | 98.2× | (43.27%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 431× | 63.58% |
| Mar 2026 | 263× | 288.95% |
| Dec 2025 | 67.7× | (11.59%) |
| Sep 2025 | 76.5× | 44.57% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.7× |
| TMCI Treace Medical Concepts, Inc. compare | 1.3× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| ELMD Electromed, Inc. compare | 2.8× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.4× |
| CLPT ClearPoint Neuro, Inc. compare | 7.0× |
| PROF Profound Medical compare | 9.9× |
| CATX Perspective Therapeutics, Inc. | 64.7× |
| QSI Quantum-Si Incorporated compare | 82.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)